UK-based clinical-stage biotechnology company TC BioPharm (Holdings) PLC (NASDAQ:TCBP) announced on Monday shareholder approval of a 25% stock dividend during its General Meeting.
The special dividend grants 0.25 American Depositary Shares (ADSs) for each ADS held on the record date of 2 January 2025, with delivery anticipated by 6 January 2025.
Trading in TC BioPharm's ADSs will pause at 17:00 hours on 2 January 2025, per Nasdaq requirements, resuming around 8 January 2025, to facilitate the dividend process. Nasdaq plans to adjust the opening price on 8 January to account for dilution from the dividend issuance.
Lilly and EVA Pharma granted regulatory approval for locally manufactured insulin in Egypt
Abbott announces dividend increase and 53 years of growth
SK bioscience begins clinical trials for mRNA Japanese encephalitis vaccine
Moberg Pharma's MOB-015 fails to meet primary endpoint in phase 3 study
Valneva reports strong, long-lasting immunity from single-dose chikungunya vaccine